Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma
Despite the relatively high long‐term disease‐free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL...
Saved in:
| Published in | The oncologist (Dayton, Ohio) Vol. 17; no. 1; pp. 80 - 90 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Durham, NC, USA
AlphaMed Press
01.01.2012
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1083-7159 1549-490X 1549-490X |
| DOI | 10.1634/theoncologist.2011-0177 |
Cover
Loading…
| Abstract | Despite the relatively high long‐term disease‐free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5‐year progression‐free survival rate of ∼50%–60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas.
摘要
霍奇金淋巴瘤（ HL ）患者采用现代联合化疗或综合治疗方案后，长期无病生存（ DFS ）率相对较高，但仍有约20%的患者死于疾病进展或复发。复发和原发难治 HL 的标准治疗是解救化疗继以大剂量化疗和自体干细胞移植（ ASCT ），其5年无进展生存率介于约50%~60%。最近开发的若干诊断和治疗方法已开始改善上述结果。功能成像、临床预后因素的细化、新型生物标记物的开发已改进了预测规程，可更好地甄选患者和确定 ASCT 的时机。此外，这些规程已开始检出适于标准 ASCT 之外更具侵袭性治疗的患者。新型解救方案有望提高 ASCT 之前的完全缓解率，ASCT后维持治疗的应用已成为目前研究的课题。本文总结上述各领域的进展。
New developments in the treatment of patients with relapsed/refractory Hodgkin's lymphoma undergoing autologous stem cell transplantation are summarized including modern prognostic markers, the role of functional imaging, the role of newer drugs, different conditioning regimens, and maintenance therapy. |
|---|---|
| AbstractList | Despite the relatively high long‐term disease‐free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5‐year progression‐free survival rate of ∼50%–60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas.
摘要
霍奇金淋巴瘤（ HL ）患者采用现代联合化疗或综合治疗方案后，长期无病生存（ DFS ）率相对较高，但仍有约20%的患者死于疾病进展或复发。复发和原发难治 HL 的标准治疗是解救化疗继以大剂量化疗和自体干细胞移植（ ASCT ），其5年无进展生存率介于约50%~60%。最近开发的若干诊断和治疗方法已开始改善上述结果。功能成像、临床预后因素的细化、新型生物标记物的开发已改进了预测规程，可更好地甄选患者和确定 ASCT 的时机。此外，这些规程已开始检出适于标准 ASCT 之外更具侵袭性治疗的患者。新型解救方案有望提高 ASCT 之前的完全缓解率，ASCT后维持治疗的应用已成为目前研究的课题。本文总结上述各领域的进展。
New developments in the treatment of patients with relapsed/refractory Hodgkin's lymphoma undergoing autologous stem cell transplantation are summarized including modern prognostic markers, the role of functional imaging, the role of newer drugs, different conditioning regimens, and maintenance therapy. New developments in the treatment of patients with relapsed/refractory Hodgkin's lymphoma undergoing autologous stem cell transplantation are summarized including modern prognostic markers, the role of functional imaging, the role of newer drugs, different conditioning regimens, and maintenance therapy. Despite the relatively high long-term disease-free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5-year progression-free survival rate of ∼50%–60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas. Despite the relatively high long-term disease-free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5-year progression-free survival rate of ∼50%-60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas. Despite the relatively high long-term disease-free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5-year progression-free survival rate of ∼50%-60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas.Despite the relatively high long-term disease-free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, ∼20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5-year progression-free survival rate of ∼50%-60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas. Despite the relatively high long-term disease-free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality regimens, similar to 20% of patients die from progressive or relapsed disease. The standard treatment for relapsed and primary refractory HL is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), which has shown a 5-year progression-free survival rate of similar to 50%-60%. Recent developments in a number of diagnostic and therapeutic modalities have begun to improve these results. Functional imaging, refinement of clinical prognostic factors, and development of novel biomarkers have improved the predictive algorithms, allowing better patient selection and timing for ASCT. In addition, these algorithms have begun to identify a group of patients who are candidates for more aggressive treatment beyond standard ASCT. Novel salvage regimens may potentially improve the rate of complete remission prior to ASCT, and the use of maintenance therapy after ASCT has become a subject of current investigation. We present a summary of developments in each of these areas. |
| Author | Hochberg, Ephraim Colpo, Anna Chen, Yi‐Bin |
| Author_xml | – sequence: 1 givenname: Anna surname: Colpo fullname: Colpo, Anna – sequence: 2 givenname: Ephraim surname: Hochberg fullname: Hochberg, Ephraim – sequence: 3 givenname: Yi‐Bin surname: Chen fullname: Chen, Yi‐Bin email: ychen6@partners.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22210089$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkctu1DAUhi1URC_wCuBd2aT4NomzAKmKgCKNGIkWiZ3lOPaMwbFT2wHN2-NoSkVZoK58jvyd_1z-U3Dkg9cAvMLoAteUvck7HbwKLmxtyhcEYVwh3DRPwAlesbZiLfp2VGLEadXgVXsMTlP6jlAJKXkGjgkhGCHenoChm2PUPsPrLPOcYDDwcs6LcCjZddYj7LRz8CZKnyYnfcFs8NB6-EU7OSU9QOmHkpgoVQ5xD6_CsP1h_XmC6_047cIon4OnRrqkX9y9Z-Drh_c33VW13nz81F2uK7VCFFUNqRVFuq91T1ulWcPVUBvSG4WRkqZnGNVGE9NzggZJDTNc93xFJDFs4LymZ-DdQXea-1EPquwVpRNTtKOMexGkFQ9_vN2JbfgpKKkbTpoicH4nEMPtrFMWo02q7C-9LvcQLeblgDWjhXz9X3I5b1EkDBX05d9T3Y_zx4QCNAdAxZBS1OYewUgsdosHdovFbrHYXSrf_lOp7MGgsp51j6__ZZ3eP7at2HzuNmVyRH8DfUzONQ |
| CitedBy_id | crossref_primary_10_1016_j_bbmt_2019_01_032 crossref_primary_10_1016_j_transci_2013_04_027 crossref_primary_10_1016_j_bbmt_2015_02_005 crossref_primary_10_14694_EdBook_AM_2012_32_143 crossref_primary_10_1016_j_clml_2021_09_003 crossref_primary_10_1080_10428194_2023_2167492 crossref_primary_10_1007_s00198_017_4032_1 crossref_primary_10_1111_bjh_15585 crossref_primary_10_1002_ajh_23660 crossref_primary_10_1007_s00277_018_3576_2 crossref_primary_10_1080_17474086_2018_1516135 crossref_primary_10_1097_MOT_0b013e32835daf68 crossref_primary_10_1007_s00277_013_1930_y crossref_primary_10_1007_s00277_024_05813_w crossref_primary_10_1016_j_bbmt_2013_09_018 crossref_primary_10_1016_j_leukres_2021_106689 crossref_primary_10_1002_cncr_30482 crossref_primary_10_1016_j_clml_2024_09_003 crossref_primary_10_21320_2500_2139_2016_9_4_406_412 crossref_primary_10_1002_stem_1798 crossref_primary_10_1007_s12254_020_00621_0 crossref_primary_10_3109_10428194_2014_887715 |
| Cites_doi | 10.1182/blood.V85.5.1381.bloodjournal8551381 10.1097/01.coc.0000209370.61355.8e 10.1182/blood.V114.22.720.720 10.1182/blood.V112.11.2601.2601 10.1056/NEJMoa1002965 10.1056/NEJMoa022473 10.3324/haematol.10661 10.1182/blood.V83.5.1193.1193 10.1182/blood.V116.21.690.690 10.1046/j.1365-2141.2001.02714.x 10.1182/blood.V116.21.31.31 10.1111/j.1365-2141.2009.08037.x 10.1093/oxfordjournals.annonc.a010542 10.1200/JCO.1993.11.4.704 10.1200/JCO.2010.29.8018 10.1200/jco.2010.28.15_suppl.3068 10.1038/sj.bmt.1700963 10.1016/j.bbmt.2007.02.013 10.1002/cncr.21587 10.1038/sj.bmt.1705416 10.1182/blood.V116.21.419.419 10.1200/JCO.2003.12.086 10.1182/blood.V97.3.616 10.1200/JCO.2005.05.022 10.1038/sj.bmt.1700913 10.1002/cncr.22911 10.1023/A:1026454831340 10.1200/JCO.2007.15.5887 10.1182/blood-2002-12-3842 10.1038/sj.bmt.1700838 10.1200/JCO.2001.19.5.1395 10.1111/j.1365-2141.2010.08492.x 10.1038/sj.bmt.1701186 10.1093/annonc/mdm090 10.1038/sj.bmt.1705544 10.1093/annonc/mdl496 10.1182/blood.V116.21.283.283 10.1056/NEJMoa0905680 10.1080/07357900701788098 10.1007/s00277-010-1113-z 10.1016/j.bbmt.2007.02.006 10.1038/sj.bmt.1702796 10.1200/JCO.2007.15.5507 10.1182/blood-2008-11-189688 10.1200/JCO.2010.30.5771 10.1002/path.1725 10.1038/sj.bmt.1704661 10.1002/cncr.11511 10.1111/j.1365-2141.2009.07727.x 10.1093/annonc/mdg496 10.1080/10428190902853136 10.1056/NEJMoa1000067 10.1155/2011/439456 10.3324/haematol.2009.019943 10.1200/JCO.1992.10.11.1682 10.1111/j.1365-2141.2011.08616.x 10.1182/blood.V114.22.3693.3693 10.1182/blood.V89.3.801 10.1182/blood.V81.5.1137.1137 10.1093/annonc/mdg710 10.1093/annonc/mdf221 10.1182/blood.V116.21.3954.3954 10.1182/blood.V116.21.3964.3964 10.1016/j.bbmt.2009.07.014 10.1056/NEJM199811193392104 10.1200/JCO.1993.11.6.1062 10.1093/annonc/mdi003 10.1016/0140-6736(93)92411-L 10.1111/j.1365-2141.2011.08594.x 10.1200/JCO.1994.12.12.2527 10.3109/10428194.2011.572324 10.1002/cncr.25216 10.1182/blood.V93.11.3632 10.1016/j.bbmt.2007.01.072 10.1111/j.1365-2141.2009.07963.x 10.1038/sj.leu.2402342 10.1182/blood-2005-11-006957 10.1093/oxfordjournals.annonc.a058662 10.1002/cncr.22714 10.1016/S0140-6736(02)08938-9 10.1093/oxfordjournals.annonc.a059242 10.1111/j.1365-2141.2003.04828.x 10.1002/cncr.11414 10.1002/cncr.23237 10.1182/blood.V112.11.3052.3052 10.1182/blood-2010-05-282756 10.1038/sj.bmt.1705951 10.1111/j.1365-2141.2010.08485.x 10.1182/blood-2002-03-0839 10.1093/annonc/mdf228 10.1093/annonc/mdi119 10.1016/j.ejca.2005.01.006 10.1023/A:1008343823292 10.1111/j.1365-2141.2009.07798.x 10.1182/blood-2004-12-4689 10.1093/annonc/mdj995 10.1016/j.bbmt.2006.08.039 10.1200/JCO.2010.31.5515 10.1200/JCO.1999.17.2.534 10.1093/annonc/mdp487 10.1046/j.1365-2141.2003.04226.x 10.1002/ajh.21664 10.1016/j.bbmt.2010.07.016 |
| ContentType | Journal Article |
| Copyright | 2012 AlphaMed Press AlphaMed Press 2011 |
| Copyright_xml | – notice: 2012 AlphaMed Press – notice: AlphaMed Press 2011 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO H94 7X8 5PM |
| DOI | 10.1634/theoncologist.2011-0177 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Oncogenes and Growth Factors Abstracts CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-490X |
| EndPage | 90 |
| ExternalDocumentID | PMC3267827 22210089 10_1634_theoncologist_2011_0177 ONCO0080 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABEJV ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH ITC LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAFWJ AAYXX ABGNP AFPKN CITATION OVT 7X7 88E 8FI 8FJ AAMMB ABUWG AEFGJ AFKRA AGXDD AIDQK AIDYY BENPR CCPQU CGR CUY CVF ECM EIF FYUFA HMCUK M1P NPM PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO UKHRP 7T5 7TO H94 7X8 5PM |
| ID | FETCH-LOGICAL-c5030-726c30eb6eb39ce478cd6f2bfc10cafb4106fe2fb820da3f4f8eb852a2f4d8863 |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Thu Aug 21 18:22:54 EDT 2025 Fri Sep 05 07:43:39 EDT 2025 Fri Sep 05 09:39:18 EDT 2025 Mon Jul 21 05:59:35 EDT 2025 Tue Jul 01 00:48:11 EDT 2025 Thu Apr 24 23:05:55 EDT 2025 Wed Jan 22 16:43:00 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5030-726c30eb6eb39ce478cd6f2bfc10cafb4106fe2fb820da3f4f8eb852a2f4d8863 |
| Notes | Genzyme (C/A); Otsuka, Millennium, Bayer (RF). Yi‐Bin Chen Disclosures: Anna Colpo Ephraim Hochberg None Proventys, Genentech (CA) ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Disclosures: Anna Colpo: None; Ephraim Hochberg: Proventys, Genentech (CA); Yi-Bin Chen: Genzyme (C/A); Otsuka, Millennium, Bayer (RF). |
| OpenAccessLink | http://theoncologist.alphamedpress.org/content/17/1/80.full.pdf |
| PMID | 22210089 |
| PQID | 1008827240 |
| PQPubID | 23462 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3267827 proquest_miscellaneous_918932643 proquest_miscellaneous_1008827240 pubmed_primary_22210089 crossref_primary_10_1634_theoncologist_2011_0177 crossref_citationtrail_10_1634_theoncologist_2011_0177 wiley_primary_10_1634_theoncologist_2011_0177_ONCO0080 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2012 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: January 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Durham, NC, USA |
| PublicationPlace_xml | – name: Durham, NC, USA – name: England |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2012 |
| Publisher | AlphaMed Press |
| Publisher_xml | – name: AlphaMed Press |
| References | 2002; 16 2007; 39 2004; 124 2006; 38 2002; 13 2010; 148 1997; 89 2002; 359 2003; 14 2011; 52 2009; 113 1999; 84 2011; 152 2011; 17 1992; 10 2007; 109 1997; 3 2009; 114 2003; 97 2005; 23 2003; 98 1993; 4 2011; 153 2010; 21 2010; 116 2009; 50 2010; 28 1999; 17 2002; 87 2004; 34 2005; 106 2001; 19 2008; 26 2006; 29 1999; 10 1999; 93 2008; 112 2009; 15 2001; 97 2003; 120 1996; 7 2007; 18 2006; 12 2011 1997; 20 1993; 81 2006; 17 2008; 19 2010; 363 1998; 339 2005; 41 2010; 362 2007; 92 2001; 27 1994; 83 1998; 21 1993; 341 1995; 6 2007; 13 2010; 85 1995; 85 2011; 2011 2001; 113 2003; 348 2002; 20 2011; 90 2007; 110 1993; 11 2005; 205 1994; 12 2009; 146 2008; 41 2005; 16 2003; 102 2006; 106 2003; 101 2009; 147 2003; 21 2010; 95 Moskowitz (2021122307520996000_B49) 2009; 114 Bonadonna (2021122307520996000_B3) 2005; 41 Fernàndez de Larrea (2021122307520996000_B95) 2010; 21 Martín (2021122307520996000_B30) 2001; 113 Younes (2021122307520996000_B90) 2003; 98 Gallamini (2021122307520996000_B6) 2011; 152 Baetz (2021122307520996000_B40) 2003; 14 Smith (2021122307520996000_B29) 2011; 153 Santoro (2021122307520996000_B44) 2007; 92 Brice (2021122307520996000_B74) 1999; 10 Younes (2021122307520996000_B79) 2010; 363 Goodman (2021122307520996000_B65) 2008; 26 Josting (2021122307520996000_B64) 2005; 23 Suyani (2021122307520996000_B43) 2011; 90 Kebriaei (2021122307520996000_B110) 2011; 17 Engert (2021122307520996000_B1) 2010; 363 Fung (2021122307520996000_B75) 2007; 13 Corradini (2021122307520996000_B77) 2011; 152 Younes (2021122307520996000_B86) 2010; 116 Zinzani (2021122307520996000_B36) 2002; 87 Visani (2021122307520996000_B62) 2010; 116 Lazarus (2021122307520996000_B106) 1999; 17 Corazzelli (2021122307520996000_B92) 2008; 112 Bierman (2021122307520996000_B98) 1993; 4 Linch (2021122307520996000_B7) 1993; 341 Wadehra (2021122307520996000_B59) 2006; 12 Josting (2021122307520996000_B34) 2005; 16 Oki (2021122307520996000_B91) 2008; 112 Fehniger (2021122307520996000_B89) 2009; 114 Schmitz (2021122307520996000_B8) 2002; 359 Schot (2021122307520996000_B25) 2007; 109 Proctor (2021122307520996000_B37) 2003; 14 Rodriguez (2021122307520996000_B33) 1999; 93 Evens (2021122307520996000_B109) 2007; 18 Sureda (2021122307520996000_B18) 2005; 16 Lazarus (2021122307520996000_B107) 2001; 27 Jabbour (2021122307520996000_B20) 2007; 109 Reece (2021122307520996000_B97) 1992; 10 Nademanee (2021122307520996000_B10) 1995; 85 Regelink (2021122307520996000_B72) 2010; 28 Lazarus (2021122307520996000_B73) 2007; 13 Böll (2021122307520996000_B87) 2010; 148 Fermé (2021122307520996000_B39) 2002; 20 Svoboda (2021122307520996000_B23) 2006; 38 Shea (2021122307520996000_B50) 2009; 50 Brice (2021122307520996000_B16) 1997; 20 Santos (2021122307520996000_B60) 2007; 13 Becherer (2021122307520996000_B21) 2002; 16 Lane (2021122307520996000_B63) 2011; 52 Moskowitz (2021122307520996000_B19) 2010; 148 Hasenclever (2021122307520996000_B14) 1998; 339 Spaepen (2021122307520996000_B22) 2003; 102 Reece (2021122307520996000_B12) 1994; 83 Tarella (2021122307520996000_B51) 2003; 97 Eich (2021122307520996000_B2) 2010; 28 Yahalom (2021122307520996000_B55) 1993; 11 Hertzberg (2021122307520996000_B35) 2006; 17 Lavoie (2021122307520996000_B13) 2005; 106 Ulrickson (2021122307520996000_B58) 2009; 15 Steidl (2021122307520996000_B28) 2010; 362 Diehl (2021122307520996000_B4) 2003; 348 Crump (2021122307520996000_B67) 1993; 11 Aparicio (2021122307520996000_B32) 1999; 10 Jones (2021122307520996000_B93) 2009; 113 Caballero (2021122307520996000_B101) 1997; 20 Schwering (2021122307520996000_B81) 2003; 101 Bierman (2021122307520996000_B100) 1996; 7 Moskowitz (2021122307520996000_B108) 2004; 124 Majhail (2021122307520996000_B69) 2009; 147 Lazarus (2021122307520996000_B66) 1992; 10 Kasamon (2021122307520996000_B94) 2010; 116 Benekli (2021122307520996000_B57) 2008; 41 Sureda (2021122307520996000_B83) 2010; 116 Rapoport (2021122307520996000_B78) 2004; 34 Fernàndez-Jiménez (2021122307520996000_B31) 1999; 84 Sweetenham (2021122307520996000_B103) 1997; 20 Rigacci (2021122307520996000_B96) 2010; 116 Arranz (2021122307520996000_B105) 1998; 21 Filmont (2021122307520996000_B24) 2007; 110 Puig (2021122307520996000_B9) 2010; 95 Chau (2021122307520996000_B41) 2003; 120 Josting (2021122307520996000_B17) 2002; 20 Moskowitz (2021122307520996000_B70) 2009; 146 Duggan (2021122307520996000_B5) 2003; 21 Nieto (2021122307520996000_B61) 2010; 116 Morschhauser (2021122307520996000_B76) 2008; 26 Wheeler (2021122307520996000_B104) 1997; 3 Josting (2021122307520996000_B52) 2010; 28 Kuruvilla (2021122307520996000_B88) 2008; 112 Banerjee (2021122307520996000_B27) 2011; 2011 Chen (2021122307520996000_B80) 2010; 116 Bierman (2021122307520996000_B15) 2002; 13 Moskowitz (2021122307520996000_B11) 2001; 97 Wendland (2021122307520996000_B68) 2006; 29 Darrington (2021122307520996000_B53) 1994; 12 Josting (2021122307520996000_B47) 2002; 13 Moskowitz (2021122307520996000_B26) 2010; 116 Fermé (2021122307520996000_B38) 1995; 6 Kuruvilla (2021122307520996000_B45) 2006; 106 Perz (2021122307520996000_B56) 2007; 39 Horning (2021122307520996000_B102) 1997; 89 Abali (2021122307520996000_B46) 2008; 26 Dutton (2021122307520996000_B84) 2005; 205 Chopra (2021122307520996000_B99) 1993; 81 Carlo-Stella (2021122307520996000_B82) 2010; 28 Sibon (2021122307520996000_B48) 2011 Johnston (2021122307520996000_B85) 2010; 85 Sureda (2021122307520996000_B54) 2001; 19 Bartlett (2021122307520996000_B42) 2007; 18 Horning (2021122307520996000_B71) 2008; 19 |
| References_xml | – volume: 89 start-page: 801 year: 1997 end-page: 813 article-title: High‐dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices publication-title: Blood – volume: 6 start-page: 543 year: 1995 end-page: 549 article-title: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease publication-title: Ann Oncol – volume: 50 start-page: 741 year: 2009 end-page: 748 article-title: Sequential high‐dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B‐cell non‐Hodgkin lymphoma: Increased toxicity without improvement in progression‐free survival publication-title: Leuk Lymphoma – volume: 3 start-page: 98 year: 1997 end-page: 106 article-title: High‐dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes publication-title: Biol Blood Marrow Transplant – volume: 152 start-page: 551 year: 2011 end-page: 560 article-title: Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses publication-title: Br J Haematol – volume: 28 start-page: 5074 year: 2010 end-page: 5080 article-title: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 14 start-page: i47 issue: suppl 1 year: 2003 end-page: i50 article-title: Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high‐dose ifosfamide, etoposide and epirubicin: A Northern Region Lymphoma Group study (UK) publication-title: Ann Oncol – volume: 16 start-page: 260 year: 2002 end-page: 267 article-title: Positron emission tomography with [18F]2‐fluoro‐D‐2‐deoxyglucose (FDG‐PET) predicts relapse of malignant lymphoma after high‐dose therapy with stem cell transplantation publication-title: Leukemia – volume: 90 start-page: 685 year: 2011 end-page: 691 article-title: Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT publication-title: Ann Hematol – volume: 112 start-page: 3052 year: 2008 article-title: Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood – volume: 7 start-page: 151 year: 1996 end-page: 156 article-title: High‐dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy publication-title: Ann Oncol – volume: 363 start-page: 640 year: 2010 end-page: 652 article-title: Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma publication-title: N Engl J Med – volume: 18 start-page: 1071 year: 2007 end-page: 1079 article-title: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 publication-title: Ann Oncol – volume: 116 start-page: 3954 year: 2010 article-title: High‐dose cyclophosphamide (Cy), rituximab, and a cancer vaccine for relapsed classical Hodgkin's lymphoma (cHL) publication-title: Blood – volume: 106 start-page: 353 year: 2006 end-page: 360 article-title: Similar response rates and superior early progression‐free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma publication-title: Cancer – volume: 81 start-page: 1137 year: 1993 end-page: 1145 article-title: The place of high‐dose BEAM therapy and autologous bone marrow transplantation in poor‐risk Hodgkin's disease. A single‐center eight‐ year study of 155 patients publication-title: Blood – volume: 109 start-page: 2481 year: 2007 end-page: 2489 article-title: Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma publication-title: Cancer – volume: 10 start-page: 1485 year: 1999 end-page: 1488 article-title: Feasibility of tandem autologous stem‐cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group publication-title: Ann Oncol – volume: 106 start-page: 1473 year: 2005 end-page: 1478 article-title: High‐dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long‐term outcome in the first 100 patients treated in Vancouver publication-title: Blood – volume: 83 start-page: 1193 year: 1994 end-page: 1199 article-title: Intensive therapy with cyclophosphamide, carmustine, etoposide +/‐ cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy publication-title: Blood – volume: 116 start-page: 4934 year: 2010 end-page: 4937 article-title: Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma publication-title: Blood – volume: 13 start-page: 1628 year: 2002 end-page: 1635 article-title: Time‐intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease publication-title: Ann Oncol – volume: 29 start-page: 189 year: 2006 end-page: 195 article-title: The impact of involved field radiation therapy for patients receiving high‐dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease publication-title: Am J Clin Oncol – volume: 124 start-page: 645 year: 2004 end-page: 652 article-title: Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease publication-title: Br J Haematol – volume: 17 start-page: iv25 issue: suppl 4 year: 2006 end-page: iv30 article-title: Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non‐Hodgkin's and Hodgkin's lymphoma publication-title: Ann Oncol – volume: 10 start-page: 1682 year: 1992 end-page: 1689 article-title: High‐dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma publication-title: J Clin Oncol – volume: 10 start-page: 593 year: 1999 end-page: 595 article-title: ESHAP is an active regimen for relapsing Hodgkin's disease publication-title: Ann Oncol – volume: 359 start-page: 2065 year: 2002 end-page: 2071 article-title: Aggressive conventional chemotherapy compared with high‐dose chemotherapy with autologous haemopoietic stem‐cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial publication-title: Lancet – volume: 362 start-page: 875 year: 2010 end-page: 885 article-title: Tumor‐associated macrophages and survival in classic Hodgkin's lymphoma publication-title: N Engl J Med – volume: 109 start-page: 486 year: 2007 end-page: 491 article-title: Early FDG‐PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma publication-title: Blood – volume: 10 start-page: 170 year: 1992 article-title: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871–1879 publication-title: Erratum in J Clin Oncol – volume: 20 start-page: 451 year: 1997 end-page: 458 article-title: BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors publication-title: Bone Marrow Transplant – volume: 17 start-page: 534 year: 1999 end-page: 545 article-title: Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry publication-title: J Clin Oncol – volume: 12 start-page: 2527 year: 1994 end-page: 2534 article-title: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high‐dose chemoradiotherapy and autologous stem‐cell transplantation for lymphoid malignancies publication-title: J Clin Oncol – volume: 113 start-page: 5920 year: 2009 end-page: 5926 article-title: Circulating clonotypic B cells in classic Hodgkin lymphoma publication-title: Blood – volume: 152 start-page: 261 year: 2011 end-page: 272 article-title: Allogeneic transplantation for Hodgkin's lymphoma publication-title: Br J Haematol – volume: 148 start-page: 890 year: 2010 end-page: 897 article-title: High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging publication-title: Br J Haematol – volume: 26 start-page: 401 year: 2008 end-page: 406 article-title: Comparison of ICE (ifosfamide‐carboplatin‐etoposide) versus DHAP (cytosine arabinoside‐cisplatin‐dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma publication-title: Cancer Invest – volume: 120 start-page: 970 year: 2003 end-page: 977 article-title: Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM‐P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non‐Hodgkin's lymphoma publication-title: Br J Haematol – volume: 34 start-page: 883 year: 2004 end-page: 890 article-title: Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma publication-title: Bone Marrow Transplant – volume: 38 start-page: 211 year: 2006 end-page: 216 article-title: Prognostic value of FDG‐PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation publication-title: Bone Marrow Transplant – volume: 116 start-page: 3964 year: 2010 article-title: Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non‐Hodgkin lymphoma publication-title: Blood – volume: 85 start-page: 1381 year: 1995 end-page: 1390 article-title: High‐dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors publication-title: Blood – volume: 13 start-page: 594 year: 2007 end-page: 600 article-title: Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma publication-title: Biol Blood Marrow Transplant – volume: 26 start-page: 5240 year: 2008 end-page: 5247 article-title: Long‐term effects of high‐dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 97 start-page: 2748 year: 2003 end-page: 2759 article-title: High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence publication-title: Cancer – volume: 18 start-page: 679 year: 2007 end-page: 688 article-title: Phase I/II trial of total lymphoid irradiation and high‐dose chemotherapy with autologous stem‐cell transplantation for relapsed and refractory Hodgkin's lymphoma publication-title: Ann Oncol – volume: 116 start-page: 690 year: 2010 article-title: Gemcitabine, busulfan and melphalan (GemBuMel) is a new high‐dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem‐cell transplant (ASCT): A contemporaneous comparison with BEAM and busulfan/melphalan (BuMel) publication-title: Blood – volume: 101 start-page: 1505 year: 2003 end-page: 1512 article-title: Loss of the B‐lineage‐specific gene expression program in Hodgkin and Reed‐Sternberg cells of Hodgkin lymphoma publication-title: Blood – volume: 26 start-page: 5980 year: 2008 end-page: 5987 article-title: Risk‐adapted salvage treatment with single or tandem autologous stem‐cell transplantation for first relapse/refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM Study Group publication-title: J Clin Oncol – volume: 15 start-page: 1447 year: 2009 end-page: 1454 article-title: Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non‐Hodgkin lymphoma: A single‐institution experience publication-title: Biol Blood Marrow Transplant – volume: 146 start-page: 158 year: 2009 end-page: 163 article-title: Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma publication-title: Br J Haematol – volume: 13 start-page: 746 year: 2007 end-page: 747 article-title: Long‐term outcome of Hodgkin disease patients following high‐dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation—a similar experience publication-title: Biol Blood Marrow Transplant – volume: 114 start-page: 720 year: 2009 article-title: Bendamustine is highly active in heavily pre‐treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant publication-title: Blood – volume: 93 start-page: 3632 year: 1999 end-page: 3636 article-title: ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease publication-title: Blood – volume: 116 start-page: 4573 year: 2010 end-page: 4579 article-title: Oxaliplatin‐based chemotherapy (dexamethasone, high‐dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma publication-title: Cancer – volume: 114 start-page: 3693 year: 2009 article-title: A Phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma publication-title: Blood – volume: 97 start-page: 616 year: 2001 end-page: 623 article-title: A 2‐step comprehensive high‐dose chemoradiotherapy second‐line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model publication-title: Blood – volume: 28 start-page: e741 year: 2010 end-page: e743 article-title: Long‐term follow‐up of tandem autologous stem‐cell transplantation in multiple myeloma publication-title: J Clin Oncol – volume: 21 start-page: 779 year: 1998 end-page: 786 article-title: Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant publication-title: Bone Marrow Transplant – volume: 110 start-page: 1361 year: 2007 end-page: 1369 article-title: The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation publication-title: Cancer – volume: 87 start-page: 816 year: 2002 end-page: 821 article-title: Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients publication-title: Haematologica – volume: 11 start-page: 1062 year: 1993 end-page: 1070 article-title: Accelerated hyperfractionated total‐lymphoid irradiation, high‐dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease publication-title: J Clin Oncol – volume: 112 start-page: 2601 year: 2008 article-title: Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R‐GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory Hodgkin lymphoma publication-title: Blood – volume: 41 start-page: 998 year: 2005 end-page: 1006 article-title: Survival in Hodgkin's disease patients—report of 25 years of experience at the Milan Cancer Institute publication-title: Eur J Cancer – volume: 20 start-page: 745 year: 1997 end-page: 752 article-title: High‐dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation publication-title: Bone Marrow Transplant – volume: 28 start-page: 4199 year: 2010 end-page: 4206 article-title: Intensified chemotherapy and dose‐reduced involved‐field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final Analysis of the German Hodgkin Study Group HD11 trial publication-title: J Clin Oncol – volume: 348 start-page: 2386 year: 2003 end-page: 2395 article-title: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's Disease publication-title: N Engl J Med – volume: 84 start-page: 1007 year: 1999 end-page: 1011 article-title: Salvage chemotherapy with mini‐BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation publication-title: Haematologica – volume: 12 start-page: 1343 year: 2006 end-page: 1349 article-title: Long‐term outcome of Hodgkin disease patients following high‐dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation publication-title: Biol Blood Marrow Transplant – volume: 23 start-page: 1522 year: 2005 end-page: 1529 article-title: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group publication-title: J Clin Oncol – volume: 21 start-page: 1211 year: 2010 end-page: 1216 article-title: Salvage chemotherapy with alternating MINE–ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem‐cell transplantation publication-title: Ann Oncol – volume: 20 start-page: 21 year: 1997 end-page: 26 article-title: Prognostic factors for survival after high‐dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Société Frana̧ise de Greffe de Moëlle publication-title: Bone Marrow Transplant – volume: 14 start-page: 1762 year: 2003 end-page: 1767 article-title: Gemcitabine, dexamethasone and cisplatin is an active and non‐toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group publication-title: Ann Oncol – volume: 28 start-page: 3068 issue: 15 suppl year: 2010 article-title: Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL) publication-title: J Clin Oncol – volume: 20 start-page: 221 year: 2002 end-page: 230 article-title: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group publication-title: J Clin Oncol – volume: 341 start-page: 1051 year: 1993 end-page: 1054 article-title: Dose intensification with autologous bone‐marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial publication-title: Lancet – volume: 205 start-page: 498 year: 2005 end-page: 506 article-title: Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR publication-title: J Pathol – volume: 116 start-page: 31 issue: 21 year: 2010 article-title: A novel high dose chemotherapy strategy with bendamustine in adjunct to etoposide, cytarabine and melphalan (BeEAM) followed by autologous stem cell rescue is safe and highly effective for the treatment of resistant/relapsed lymphoma patients: A phase I‐II study on 44 patients publication-title: Blood – volume: 98 start-page: 310 year: 2003 end-page: 314 article-title: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease publication-title: Cancer – volume: 41 start-page: 613 year: 2008 end-page: 619 article-title: Intensive conditioning regimen of etoposide (VP‐16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma publication-title: Bone Marrow Transplant – volume: 363 start-page: 1812 year: 2010 end-page: 1821 article-title: Brentuximab vedotin (SGN‐35) for relapsed CD30‐positive lymphomas publication-title: N Engl J Med – volume: 147 start-page: 129 year: 2009 end-page: 139 article-title: Long‐term survival and late relapse in 2‐year survivors of autologous haematopoietic cell transplantation for Hodgkin and non‐Hodgkin lymphoma publication-title: Br J Haematol – volume: 153 start-page: 358 year: 2011 end-page: 363 article-title: Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres publication-title: Br J Haematol – volume: 92 start-page: 35 year: 2007 end-page: 41 article-title: Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma publication-title: Haematologica – volume: 19 start-page: iv120 issue: suppl 4 year: 2008 end-page: iv1 article-title: Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort [abstract 18] publication-title: Ann Oncol – volume: 19 start-page: 1395 year: 2001 end-page: 1404 article-title: Autologous stem‐cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autológo de Médula Osea Spanish Cooperative Group publication-title: J Clin Oncol – volume: 20 start-page: 467 year: 2002 end-page: 475 article-title: Intensive salvage therapy with high‐dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'tudes des Lymphomes de l'Adulte H89 trial publication-title: J Clin Oncol – volume: 339 start-page: 1506 year: 1998 end-page: 1514 article-title: A prognostic score for advanced Hodgkin's disease publication-title: N Engl J Med – volume: 116 start-page: 419 year: 2010 article-title: Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant publication-title: Blood – volume: 16 start-page: 625 year: 2005 end-page: 633 article-title: Prognostic factors affecting long‐term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse publication-title: Ann Oncol – volume: 11 start-page: 704 year: 1993 end-page: 711 article-title: High‐dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant publication-title: J Clin Oncol – volume: 17 start-page: 412 year: 2011 end-page: 420 article-title: Intravenous busulfan plus melphalan is a highly effective, well‐tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies publication-title: Biology Blood and Marrow Transplant – volume: 85 start-page: 320 year: 2010 end-page: 324 article-title: A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma publication-title: Am J Hematol – volume: 112 start-page: 831 year: 2008 end-page: 836 article-title: Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma publication-title: Cancer – volume: 4 start-page: 767 year: 1993 end-page: 773 article-title: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long‐term follow‐up in 128 patients publication-title: Ann Oncol – volume: 102 start-page: 53 year: 2003 end-page: 59 article-title: Prognostic value of pretransplantation positron emission tomography using fluorine 18‐fluorodeoxyglucose in patients with aggressive lymphoma treated with high‐dose chemotherapy and stem cell transplantation publication-title: Blood – volume: 113 start-page: 161 year: 2001 end-page: 171 article-title: Long‐term follow‐up in patients treated with Mini‐BEAM as salvage therapy for relapsed or refractory Hodgkin's disease publication-title: Br J Haematol – volume: 13 start-page: 1370 year: 2002 end-page: 1377 article-title: The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation publication-title: Ann Oncol – volume: 95 start-page: 1496 year: 2010 end-page: 1502 article-title: Different response to salvage chemotherapy but similar post‐transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma publication-title: Haematologica – volume: 116 start-page: 283 year: 2010 article-title: Results of a pivotal phase 2 study of brentuximab vedotin (SGN‐35) in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood – volume: 2011 start-page: 439 year: 2011 end-page: 456 article-title: Recent advances in the pathobiology of Hodgkin's lymphoma: Potential impact on diagnostic, predictive, and therapeutic strategies publication-title: Adv Hematol – volume: 39 start-page: 41 year: 2007 end-page: 47 article-title: LACE‐conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: Treatment outcome and risk factor analysis in 67 patients from a single centre publication-title: Bone Marrow Transplant – volume: 21 start-page: 607 year: 2003 end-page: 614 article-title: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial publication-title: J Clin Oncol – volume: 16 start-page: 116 year: 2005 end-page: 123 article-title: Cologne high‐dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) publication-title: Ann Oncol – volume: 13 start-page: 778 year: 2007 end-page: 789 article-title: Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis publication-title: Biol Blood Marrow Transplant – volume: 52 start-page: 1363 year: 2011 end-page: 1366 article-title: High‐dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma publication-title: Leuk Lymphoma – volume: 27 start-page: 387 year: 2001 end-page: 396 article-title: Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the Autologous Blood and Marrow Transplant Registry (ABMTR) publication-title: Bone Marrow Transplant – volume: 148 start-page: 480 year: 2010 end-page: 482 article-title: Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma publication-title: Br J Haematol – year: 2011 article-title: Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low‐toxicity regimen for first‐relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: A prospective monocentre study on 34 patients publication-title: Br J Haemat – volume: 85 start-page: 1381 year: 1995 ident: 2021122307520996000_B10 article-title: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors publication-title: Blood doi: 10.1182/blood.V85.5.1381.bloodjournal8551381 – volume: 29 start-page: 189 year: 2006 ident: 2021122307520996000_B68 article-title: The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease publication-title: Am J Clin Oncol doi: 10.1097/01.coc.0000209370.61355.8e – volume: 114 start-page: 720 year: 2009 ident: 2021122307520996000_B49 article-title: Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant publication-title: Blood doi: 10.1182/blood.V114.22.720.720 – volume: 112 start-page: 2601 year: 2008 ident: 2021122307520996000_B92 article-title: Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood.V112.11.2601.2601 – volume: 363 start-page: 1812 year: 2010 ident: 2021122307520996000_B79 article-title: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas publication-title: N Engl J Med doi: 10.1056/NEJMoa1002965 – volume: 348 start-page: 2386 year: 2003 ident: 2021122307520996000_B4 article-title: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's Disease publication-title: N Engl J Med doi: 10.1056/NEJMoa022473 – volume: 92 start-page: 35 year: 2007 ident: 2021122307520996000_B44 article-title: Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma publication-title: Haematologica doi: 10.3324/haematol.10661 – volume: 83 start-page: 1193 year: 1994 ident: 2021122307520996000_B12 article-title: Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy publication-title: Blood doi: 10.1182/blood.V83.5.1193.1193 – volume: 19 start-page: iv120 issue: suppl 4 year: 2008 ident: 2021122307520996000_B71 article-title: Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort [abstract 18] publication-title: Ann Oncol – volume: 116 start-page: 690 year: 2010 ident: 2021122307520996000_B61 article-title: Gemcitabine, busulfan and melphalan (GemBuMel) is a new high-dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant (ASCT): A contemporaneous comparison with BEAM and busulfan/melphalan (BuMel) publication-title: Blood doi: 10.1182/blood.V116.21.690.690 – volume: 113 start-page: 161 year: 2001 ident: 2021122307520996000_B30 article-title: Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2001.02714.x – volume: 116 start-page: 31 issue: 21 year: 2010 ident: 2021122307520996000_B62 article-title: A novel high dose chemotherapy strategy with bendamustine in adjunct to etoposide, cytarabine and melphalan (BeEAM) followed by autologous stem cell rescue is safe and highly effective for the treatment of resistant/relapsed lymphoma patients: A phase I-II study on 44 patients publication-title: Blood doi: 10.1182/blood.V116.21.31.31 – volume: 148 start-page: 890 year: 2010 ident: 2021122307520996000_B19 article-title: High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2009.08037.x – volume: 7 start-page: 151 year: 1996 ident: 2021122307520996000_B100 article-title: High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a010542 – volume: 11 start-page: 704 year: 1993 ident: 2021122307520996000_B67 article-title: High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant publication-title: J Clin Oncol doi: 10.1200/JCO.1993.11.4.704 – volume: 28 start-page: 4199 year: 2010 ident: 2021122307520996000_B2 article-title: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final Analysis of the German Hodgkin Study Group HD11 trial publication-title: J Clin Oncol doi: 10.1200/JCO.2010.29.8018 – volume: 28 start-page: 3068 issue: 15 suppl year: 2010 ident: 2021122307520996000_B82 article-title: Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL) publication-title: J Clin Oncol doi: 10.1200/jco.2010.28.15_suppl.3068 – volume: 20 start-page: 745 year: 1997 ident: 2021122307520996000_B103 article-title: High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1700963 – volume: 13 start-page: 778 year: 2007 ident: 2021122307520996000_B73 article-title: Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2007.02.013 – volume: 106 start-page: 353 year: 2006 ident: 2021122307520996000_B45 article-title: Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma publication-title: Cancer doi: 10.1002/cncr.21587 – volume: 38 start-page: 211 year: 2006 ident: 2021122307520996000_B23 article-title: Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1705416 – volume: 116 start-page: 419 year: 2010 ident: 2021122307520996000_B83 article-title: Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant publication-title: Blood doi: 10.1182/blood.V116.21.419.419 – volume: 21 start-page: 607 year: 2003 ident: 2021122307520996000_B5 article-title: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial publication-title: J Clin Oncol doi: 10.1200/JCO.2003.12.086 – volume: 97 start-page: 616 year: 2001 ident: 2021122307520996000_B11 article-title: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model publication-title: Blood doi: 10.1182/blood.V97.3.616 – volume: 23 start-page: 1522 year: 2005 ident: 2021122307520996000_B64 article-title: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.022 – volume: 20 start-page: 451 year: 1997 ident: 2021122307520996000_B101 article-title: BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1700913 – volume: 110 start-page: 1361 year: 2007 ident: 2021122307520996000_B24 article-title: The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation publication-title: Cancer doi: 10.1002/cncr.22911 – volume: 10 start-page: 593 year: 1999 ident: 2021122307520996000_B32 article-title: ESHAP is an active regimen for relapsing Hodgkin's disease publication-title: Ann Oncol doi: 10.1023/A:1026454831340 – volume: 26 start-page: 5980 year: 2008 ident: 2021122307520996000_B76 article-title: Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.5887 – volume: 102 start-page: 53 year: 2003 ident: 2021122307520996000_B22 article-title: Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation publication-title: Blood doi: 10.1182/blood-2002-12-3842 – volume: 84 start-page: 1007 year: 1999 ident: 2021122307520996000_B31 article-title: Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation publication-title: Haematologica – volume: 20 start-page: 21 year: 1997 ident: 2021122307520996000_B16 article-title: Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Société Frana̧ise de Greffe de Moëlle publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1700838 – volume: 19 start-page: 1395 year: 2001 ident: 2021122307520996000_B54 article-title: Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autológo de Médula Osea Spanish Cooperative Group publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.5.1395 – volume: 152 start-page: 261 year: 2011 ident: 2021122307520996000_B77 article-title: Allogeneic transplantation for Hodgkin's lymphoma publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2010.08492.x – volume: 21 start-page: 779 year: 1998 ident: 2021122307520996000_B105 article-title: Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1701186 – volume: 18 start-page: 1071 year: 2007 ident: 2021122307520996000_B42 article-title: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 publication-title: Ann Oncol doi: 10.1093/annonc/mdm090 – volume: 39 start-page: 41 year: 2007 ident: 2021122307520996000_B56 article-title: LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: Treatment outcome and risk factor analysis in 67 patients from a single centre publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1705544 – volume: 18 start-page: 679 year: 2007 ident: 2021122307520996000_B109 article-title: Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma publication-title: Ann Oncol doi: 10.1093/annonc/mdl496 – volume: 116 start-page: 283 year: 2010 ident: 2021122307520996000_B80 article-title: Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood.V116.21.283.283 – volume: 10 start-page: 170 year: 1992 ident: 2021122307520996000_B97 article-title: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871–1879 publication-title: Erratum in J Clin Oncol – volume: 362 start-page: 875 year: 2010 ident: 2021122307520996000_B28 article-title: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0905680 – volume: 26 start-page: 401 year: 2008 ident: 2021122307520996000_B46 article-title: Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma publication-title: Cancer Invest doi: 10.1080/07357900701788098 – volume: 90 start-page: 685 year: 2011 ident: 2021122307520996000_B43 article-title: Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT publication-title: Ann Hematol doi: 10.1007/s00277-010-1113-z – volume: 13 start-page: 746 year: 2007 ident: 2021122307520996000_B60 article-title: Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation—a similar experience publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2007.02.006 – volume: 27 start-page: 387 year: 2001 ident: 2021122307520996000_B107 article-title: Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the Autologous Blood and Marrow Transplant Registry (ABMTR) publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1702796 – volume: 26 start-page: 5240 year: 2008 ident: 2021122307520996000_B65 article-title: Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.5507 – volume: 113 start-page: 5920 year: 2009 ident: 2021122307520996000_B93 article-title: Circulating clonotypic B cells in classic Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2008-11-189688 – volume: 28 start-page: 5074 year: 2010 ident: 2021122307520996000_B52 article-title: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.5771 – volume: 205 start-page: 498 year: 2005 ident: 2021122307520996000_B84 article-title: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR publication-title: J Pathol doi: 10.1002/path.1725 – volume: 34 start-page: 883 year: 2004 ident: 2021122307520996000_B78 article-title: Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1704661 – volume: 98 start-page: 310 year: 2003 ident: 2021122307520996000_B90 article-title: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease publication-title: Cancer doi: 10.1002/cncr.11511 – volume: 146 start-page: 158 year: 2009 ident: 2021122307520996000_B70 article-title: Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2009.07727.x – volume: 14 start-page: 1762 year: 2003 ident: 2021122307520996000_B40 article-title: Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group publication-title: Ann Oncol doi: 10.1093/annonc/mdg496 – volume: 50 start-page: 741 year: 2009 ident: 2021122307520996000_B50 article-title: Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: Increased toxicity without improvement in progression-free survival publication-title: Leuk Lymphoma doi: 10.1080/10428190902853136 – volume: 363 start-page: 640 year: 2010 ident: 2021122307520996000_B1 article-title: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1000067 – volume: 2011 start-page: 439 year: 2011 ident: 2021122307520996000_B27 article-title: Recent advances in the pathobiology of Hodgkin's lymphoma: Potential impact on diagnostic, predictive, and therapeutic strategies publication-title: Adv Hematol doi: 10.1155/2011/439456 – volume: 95 start-page: 1496 year: 2010 ident: 2021122307520996000_B9 article-title: Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma publication-title: Haematologica doi: 10.3324/haematol.2009.019943 – volume: 10 start-page: 1682 year: 1992 ident: 2021122307520996000_B66 article-title: High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.1992.10.11.1682 – volume: 153 start-page: 358 year: 2011 ident: 2021122307520996000_B29 article-title: Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2011.08616.x – volume: 114 start-page: 3693 year: 2009 ident: 2021122307520996000_B89 article-title: A Phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood.V114.22.3693.3693 – volume: 89 start-page: 801 year: 1997 ident: 2021122307520996000_B102 article-title: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices publication-title: Blood doi: 10.1182/blood.V89.3.801 – volume: 81 start-page: 1137 year: 1993 ident: 2021122307520996000_B99 article-title: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patients publication-title: Blood doi: 10.1182/blood.V81.5.1137.1137 – volume: 14 start-page: i47 issue: suppl 1 year: 2003 ident: 2021122307520996000_B37 article-title: Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: A Northern Region Lymphoma Group study (UK) publication-title: Ann Oncol doi: 10.1093/annonc/mdg710 – volume: 13 start-page: 1628 year: 2002 ident: 2021122307520996000_B47 article-title: Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease publication-title: Ann Oncol doi: 10.1093/annonc/mdf221 – volume: 116 start-page: 3954 year: 2010 ident: 2021122307520996000_B94 article-title: High-dose cyclophosphamide (Cy), rituximab, and a cancer vaccine for relapsed classical Hodgkin's lymphoma (cHL) publication-title: Blood doi: 10.1182/blood.V116.21.3954.3954 – volume: 116 start-page: 3964 year: 2010 ident: 2021122307520996000_B86 article-title: Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood.V116.21.3964.3964 – volume: 20 start-page: 221 year: 2002 ident: 2021122307520996000_B17 article-title: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group publication-title: J Clin Oncol – volume: 15 start-page: 1447 year: 2009 ident: 2021122307520996000_B58 article-title: Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: A single-institution experience publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2009.07.014 – volume: 339 start-page: 1506 year: 1998 ident: 2021122307520996000_B14 article-title: A prognostic score for advanced Hodgkin's disease publication-title: N Engl J Med doi: 10.1056/NEJM199811193392104 – volume: 11 start-page: 1062 year: 1993 ident: 2021122307520996000_B55 article-title: Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease publication-title: J Clin Oncol doi: 10.1200/JCO.1993.11.6.1062 – volume: 16 start-page: 116 year: 2005 ident: 2021122307520996000_B34 article-title: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) publication-title: Ann Oncol doi: 10.1093/annonc/mdi003 – volume: 341 start-page: 1051 year: 1993 ident: 2021122307520996000_B7 article-title: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial publication-title: Lancet doi: 10.1016/0140-6736(93)92411-L – year: 2011 ident: 2021122307520996000_B48 article-title: Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: A prospective monocentre study on 34 patients publication-title: Br J Haemat doi: 10.1111/j.1365-2141.2011.08594.x – volume: 12 start-page: 2527 year: 1994 ident: 2021122307520996000_B53 article-title: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies publication-title: J Clin Oncol doi: 10.1200/JCO.1994.12.12.2527 – volume: 52 start-page: 1363 year: 2011 ident: 2021122307520996000_B63 article-title: High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma publication-title: Leuk Lymphoma doi: 10.3109/10428194.2011.572324 – volume: 20 start-page: 467 year: 2002 ident: 2021122307520996000_B39 article-title: Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'tudes des Lymphomes de l'Adulte H89 trial publication-title: J Clin Oncol – volume: 116 start-page: 4573 year: 2010 ident: 2021122307520996000_B96 article-title: Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma publication-title: Cancer doi: 10.1002/cncr.25216 – volume: 93 start-page: 3632 year: 1999 ident: 2021122307520996000_B33 article-title: ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease publication-title: Blood doi: 10.1182/blood.V93.11.3632 – volume: 13 start-page: 594 year: 2007 ident: 2021122307520996000_B75 article-title: Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2007.01.072 – volume: 3 start-page: 98 year: 1997 ident: 2021122307520996000_B104 article-title: High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes publication-title: Biol Blood Marrow Transplant – volume: 148 start-page: 480 year: 2010 ident: 2021122307520996000_B87 article-title: Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2009.07963.x – volume: 87 start-page: 816 year: 2002 ident: 2021122307520996000_B36 article-title: Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients publication-title: Haematologica – volume: 16 start-page: 260 year: 2002 ident: 2021122307520996000_B21 article-title: Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation publication-title: Leukemia doi: 10.1038/sj.leu.2402342 – volume: 109 start-page: 486 year: 2007 ident: 2021122307520996000_B25 article-title: Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma publication-title: Blood doi: 10.1182/blood-2005-11-006957 – volume: 4 start-page: 767 year: 1993 ident: 2021122307520996000_B98 article-title: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a058662 – volume: 109 start-page: 2481 year: 2007 ident: 2021122307520996000_B20 article-title: Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma publication-title: Cancer doi: 10.1002/cncr.22714 – volume: 359 start-page: 2065 year: 2002 ident: 2021122307520996000_B8 article-title: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08938-9 – volume: 6 start-page: 543 year: 1995 ident: 2021122307520996000_B38 article-title: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a059242 – volume: 124 start-page: 645 year: 2004 ident: 2021122307520996000_B108 article-title: Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2003.04828.x – volume: 97 start-page: 2748 year: 2003 ident: 2021122307520996000_B51 article-title: High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence publication-title: Cancer doi: 10.1002/cncr.11414 – volume: 112 start-page: 831 year: 2008 ident: 2021122307520996000_B91 article-title: Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma publication-title: Cancer doi: 10.1002/cncr.23237 – volume: 112 start-page: 3052 year: 2008 ident: 2021122307520996000_B88 article-title: Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood.V112.11.3052.3052 – volume: 116 start-page: 4934 year: 2010 ident: 2021122307520996000_B26 article-title: Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2010-05-282756 – volume: 41 start-page: 613 year: 2008 ident: 2021122307520996000_B57 article-title: Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1705951 – volume: 152 start-page: 551 year: 2011 ident: 2021122307520996000_B6 article-title: Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2010.08485.x – volume: 101 start-page: 1505 year: 2003 ident: 2021122307520996000_B81 article-title: Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2002-03-0839 – volume: 13 start-page: 1370 year: 2002 ident: 2021122307520996000_B15 article-title: The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation publication-title: Ann Oncol doi: 10.1093/annonc/mdf228 – volume: 16 start-page: 625 year: 2005 ident: 2021122307520996000_B18 article-title: Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse publication-title: Ann Oncol doi: 10.1093/annonc/mdi119 – volume: 41 start-page: 998 year: 2005 ident: 2021122307520996000_B3 article-title: Survival in Hodgkin's disease patients—report of 25 years of experience at the Milan Cancer Institute publication-title: Eur J Cancer doi: 10.1016/j.ejca.2005.01.006 – volume: 10 start-page: 1485 year: 1999 ident: 2021122307520996000_B74 article-title: Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group publication-title: Ann Oncol doi: 10.1023/A:1008343823292 – volume: 147 start-page: 129 year: 2009 ident: 2021122307520996000_B69 article-title: Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2009.07798.x – volume: 106 start-page: 1473 year: 2005 ident: 2021122307520996000_B13 article-title: High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver publication-title: Blood doi: 10.1182/blood-2004-12-4689 – volume: 17 start-page: iv25 issue: suppl 4 year: 2006 ident: 2021122307520996000_B35 article-title: Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma publication-title: Ann Oncol doi: 10.1093/annonc/mdj995 – volume: 12 start-page: 1343 year: 2006 ident: 2021122307520996000_B59 article-title: Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2006.08.039 – volume: 28 start-page: e741 year: 2010 ident: 2021122307520996000_B72 article-title: Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma publication-title: J Clin Oncol doi: 10.1200/JCO.2010.31.5515 – volume: 17 start-page: 534 year: 1999 ident: 2021122307520996000_B106 article-title: Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.2.534 – volume: 21 start-page: 1211 year: 2010 ident: 2021122307520996000_B95 article-title: Salvage chemotherapy with alternating MINE–ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation publication-title: Ann Oncol doi: 10.1093/annonc/mdp487 – volume: 120 start-page: 970 year: 2003 ident: 2021122307520996000_B41 article-title: Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2003.04226.x – volume: 85 start-page: 320 year: 2010 ident: 2021122307520996000_B85 article-title: A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma publication-title: Am J Hematol doi: 10.1002/ajh.21664 – volume: 17 start-page: 412 year: 2011 ident: 2021122307520996000_B110 article-title: Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies publication-title: Biology Blood and Marrow Transplant doi: 10.1016/j.bbmt.2010.07.016 |
| SSID | ssj0015932 |
| Score | 2.1681554 |
| Snippet | Despite the relatively high long‐term disease‐free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined... Despite the relatively high long-term disease-free survival (DFS) rate for patients with Hodgkin lymphoma (HL) with modern combination chemotherapy or combined... New developments in the treatment of patients with relapsed/refractory Hodgkin's lymphoma undergoing autologous stem cell transplantation are summarized... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 80 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autologous stem cell transplant Combined Modality Therapy Disease-Free Survival Hematopoietic Stem Cell Transplantation - methods High‐dose chemotherapy Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin Disease - surgery Hodgkin's lymphoma Humans Lymphoma Prognosis Recurrence Salvage Therapy Transplantation Conditioning Treatment Outcome |
| Title | Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2011-0177 https://www.ncbi.nlm.nih.gov/pubmed/22210089 https://www.proquest.com/docview/1008827240 https://www.proquest.com/docview/918932643 https://pubmed.ncbi.nlm.nih.gov/PMC3267827 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJvykpGQOFRZ0sR5HaGAKqTdXrpSOUV-hXbVdapteyi_nhnbSVpKxcKhUZVn4-_LZMb9ZoaQdzqJGC9EHPA8rgIWKRYUTIQBA2dARgpCAImJwmfn6eiCfZsm0042ZrNL1uJU_vxjXsn_oArrAFfMkv0HZNuTwgr4DvjCEhCG5Y0wboorYVbQxmoy-Mb2o0VdK1Zo7uO8PLaBMKvlghuvLPQpLMuVVk5erqtr23Zn2x_V6odt0JWt-ostIF17u33Zsao2ttI18APd08986xX449m83plYGNaLpcuhMaa1_aNazlpFGfCIz686gYGzgN_nwSdfDtzPRlhZRzMbob0FZdi2LpzumdjsgErOXrouTgdmPI0ZjD2mcrZ3dOomcweu6csOuMsriy74OVinqOjea63asNl0m9yJIJjABh-T8bT9rykBF9Yr_-C6H45cFatG-_PsuzAHccmhvHY37LF-y-QBue8DDvrRsechuaXNI3L3zEsqHhPlSUQdiWhd0Y5EFElEkUT0NxLRuaENiSiQiHYkop5E71e0odATcvH1y2Q4CnzrjUAmYPaDLEplHGqRahEXUrMslyqtIlHJQSh5JdggTCsdVQIcSMXjilW5FnkS8ahiKs_T-Ck5MbXRzwlVSkVhIRRjCXxUzFmYcyVFmFqFZNYjaTOapfR16bE9yqLE-BQQKfcQKRGREhHpkbA9cOlKs_z9kLcNXCWYURw-bjQMJ5buhlgzA_-2R-iRfYpBjtEOi3vkmUO4vW5DjR7J9rBvd8Aq7vtbzHxmq7nDGcFLx2GwLLnprZTj8-EY470XR3_MS3Kve0RfkZP19Ua_Bhd6Ld7YJ-AXGpPOIw |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+status+of+autologous+stem+cell+transplantation+in+relapsed+and+refractory+Hodgkin%27s+lymphoma&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Colpo%2C+Anna&rft.au=Hochberg%2C+Ephraim&rft.au=Chen%2C+Yi-Bin&rft.date=2012-01-01&rft.eissn=1549-490X&rft.volume=17&rft.issue=1&rft.spage=80&rft_id=info:doi/10.1634%2Ftheoncologist.2011-0177&rft_id=info%3Apmid%2F22210089&rft.externalDocID=22210089 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |